On this page
PNPO
pyridoxamine 5'-phosphate oxidase
PNPO is located on the long (q) arm of chromosome 17, at band 17q21.32. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 17 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The PNPO gene, located on chromosome 17, encodes pyridoxamine 5'-phosphate oxidase, an enzyme responsible for activating vitamin B6 in the body. This protein transforms dietary forms of vitamin B6 into pyridoxal 5'-phosphate (PLP), the biologically active form required for hundreds of cellular reactions. PLP serves as a cofactor for enzymes involved in amino acid metabolism, neurotransmitter synthesis, and red blood cell formation.
Pathogenic variants in PNPO are inherited in an autosomal recessive pattern, meaning affected individuals carry alterations in both gene copies. When enzyme activity is severely reduced or absent, PLP cannot be generated in sufficient amounts, resulting in neurological dysfunction that typically manifests within hours to days after birth. The gene is expressed throughout the body, with highest levels observed in liver tissue.
What the gene does
Pyridoxamine 5'-phosphate oxidase catalyses the final step in the cellular activation of vitamin B6. The enzyme chemically modifies two dietary forms of the vitamin-pyridoxine and pyridoxamine-through oxidation reactions, converting them into pyridoxal 5'-phosphate. This conversion is essential because only PLP can function as a cofactor for enzymes that build and break down amino acids, synthesise neurotransmitters such as serotonin and dopamine, and maintain normal brain development.
The enzyme requires flavin mononucleotide (FMN) as a cofactor to carry out its oxidation reactions. Within cells, the protein functions as part of the broader vitamin B6 salvage pathway, ensuring that even as PLP is consumed in metabolic reactions, fresh supplies can be regenerated from dietary precursors. Loss of enzyme function therefore creates a bottleneck in vitamin B6 metabolism, starving PLP-dependent processes throughout the body despite adequate dietary vitamin intake.
Video: Genetics 101
Chromosome location
PNPO is located on the long arm of chromosome 17 at position 21.32 (17q21.32). The gene spans a relatively compact genomic region and encodes a transcript that is translated into a 261-amino acid protein. This chromosomal region contains multiple genes involved in metabolic processes, though PNPO functions independently in vitamin B6 activation.
Protein structure
Domain architecture has not been experimentally characterised in detail for this protein. The 261-amino acid sequence folds into a structure that accommodates binding sites for both the flavin mononucleotide cofactor and the vitamin B6 substrates. Pathogenic variants throughout the protein sequence can destabilise the overall fold or directly interfere with the catalytic mechanism, reducing enzyme activity.
Key variants
Pathogenic variants in PNPO typically result in amino acid substitutions that impair enzyme stability or catalytic efficiency. Most reported variants are missense changes that reduce the protein's ability to bind its substrates or the FMN cofactor. Loss-of-function variants prevent the enzyme from converting dietary vitamin B6 into pyridoxal 5'-phosphate, creating a functional deficiency even when vitamin intake is normal. The severity of clinical features often correlates with residual enzyme activity, though even partial deficiency can cause significant neurological impairment.
No pathogenic or likely-pathogenic ClinVar variants recorded yet for this gene.
Associated conditions
Bi-allelic pathogenic variants in PNPO cause pyridoxal phosphate-responsive seizures, a rare metabolic disorder characterised by severe epilepsy beginning in the neonatal period or early infancy. Affected infants typically present with refractory seizures that do not respond to standard antiepileptic medications but improve dramatically with pyridoxal phosphate supplementation. The condition reflects the brain's critical dependence on adequate PLP for neurotransmitter synthesis; without sufficient active vitamin B6, inhibitory and excitatory signalling becomes unbalanced, triggering seizure activity. Research suggests early intervention may help reduce the risk of developmental delay and neurological damage.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic PNPO variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
PNPO appears on several NHS England clinical gene panels reflecting its role in early-onset neurological and metabolic disease. The gene holds green (definitive evidence) status on the DDG2P panel, the Early Onset or Syndromic Epilepsy panel (R59), the Likely Inborn Error of Metabolism panel (R98), and the Undiagnosed Metabolic Disorders panel. This classification supports its use in diagnostic genomic testing for infants presenting with unexplained seizures or suspected metabolic conditions in NHS Genomic Medicine Service pathways.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What happens if PNPO enzyme activity is reduced?
Reduced PNPO activity prevents the body from converting dietary vitamin B6 into pyridoxal 5'-phosphate, the active form needed for neurotransmitter production and many other cellular processes. This deficiency typically causes severe seizures in early infancy that respond to pyridoxal phosphate supplementation.
How is PNPO deficiency inherited?
PNPO deficiency follows autosomal recessive inheritance, meaning an individual must inherit pathogenic variants in both copies of the gene (one from each parent) to develop the condition. Parents who carry one variant are typically unaffected but have a 25% chance with each pregnancy of having an affected child.
Can dietary vitamin B6 supplementation treat PNPO deficiency?
Standard dietary vitamin B6 (pyridoxine) is generally ineffective because the defective enzyme cannot convert it to the active form. Treatment requires direct supplementation with pyridoxal 5'-phosphate, which bypasses the enzymatic defect and supplies the active cofactor directly to cells.